Professional Summary »
Practice Locations »
Referring Physicians »
Biography
Esther Nie MD, PhD is currently a Neuroimmunology Fellow with a special focus on neuroimmuno-oncology. She completed Adult Neurology Residency at Stanford. Dr. Nie's clinical interests include neurological presentations of CAR-T neurotoxicity, BITE therapies, and CNS/PNS demyelinating diseases. Her research interests include: microglial response in CAR-T therapy, steroid effects on the CAR-T/neurological outcomes, and enhancing repair after brain injury.
View Full Biography »
Professional Summary
Education & Certifications
- Fellowship: Stanford University Dept of Neurology (2023) CA
- Board Certification: American Board of Psychiatry and Neurology, Neurology (2022)
- Residency: Stanford University Neurology Residency (2022) CA
- Internship: Cedars Sinai Medical Center Internal Medicine Residency (2019) CA
- Medical Education: UCLA David Geffen School Of Medicine Registrar (2018) CA
- M.D., UCLA David Geffen School of Medicine, Medicine (2018)
- Ph.D., UCLA David Geffen School of Medicine, Neuroscience (2016)
- B.S., Yale University, Molecular Biophysics and Biochemistry (2009)
Publications
-
GDF10 is a signal for axonal sprouting and functional recovery after stroke
Li, S., Nie, E. H., Yin, Y., Benowitz, L. I., Tung, S., Vinters, H. V., … Carmichael, S. T. (2015). GDF10 is a signal for axonal sprouting and functional recovery after stroke. NATURE NEUROSCIENCE, 18(12), 1737–45. -
GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.
Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., … Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. -
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy
Nie, E., Ahmadian, S., Bharadwaj, S., Acosta-Alvarez, L., Threlkeld, Z., Frank, M., … Vogel, H. (2022). Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with CD19 CAR T-cell lymphoma therapy. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. OXFORD UNIV PRESS INC. -
Primary central nervous system histiocytic sarcoma presenting as neuromyelitis optica
Nirschl, J., Rogawski, D., McDonald, J., Nie, E., Schwartz, N., Scott, B., … Vogel, H. (2022). Primary central nervous system histiocytic sarcoma presenting as neuromyelitis optica. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. OXFORD UNIV PRESS INC. -
A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma.
Rogawski, D. S., Nirschl, J. J., McDonald, J., Nie, E., Schwartz, N. U., Vogel, H., … Kipp, L. B. (2022). A rare neuromyelitis optica mimic: Primary CNS histiocytic sarcoma. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1651–1654. -
MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS
Monje, M., Majzner, R., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., … Mackall, C. (2022). MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC. -
Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
Nie, E. H., Ahmadian, S. S., Bharadwaj, S. N., Acosta-Alvarez, L., Threlkeld, Z. D., Frank, M. J., … Vogel, H. (2023). Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma. Journal of Neuropathology and Experimental Neurology. -
HLA-DR4-positive Vogt-Koyanagi-Harada (VKH) Syndrome: Review of pathophysiology and clinical correlation (P1-1.Virtual)
Loeffler, J., Nie, E., & Han, M. (2022). HLA-DR4-positive Vogt-Koyanagi-Harada (VKH) Syndrome: Review of pathophysiology and clinical correlation (P1-1.Virtual). NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells
Majzner, R. G., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., … Mackall, C. L. (2022). Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T cells. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
SARS-CoV-2 Vaccine Immune Response on Anti-Complement Therapy, Eculizumab
Sattarnezhad, N., Sumera, J., McDonald, J., Nie, E., Tomczak, A., Joseph, Y., … Han, M. (2023). SARS-CoV-2 Vaccine Immune Response on Anti-Complement Therapy, Eculizumab. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) in conjunction with Allogeneic Bone Marrow Transplantation and Autoimmune Neutropenia: A study of two companion cases and institutional review of the MOGAD clinical phenotype spectrum
Nie, E., McDonald, J., Dunn, J., & Han, M. (2023). Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) in conjunction with Allogeneic Bone Marrow Transplantation and Autoimmune Neutropenia: A study of two companion cases and institutional review of the MOGAD clinical phenotype spectrum. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Epidemiological and Clinical Outcome Determinants of Post-COVID-19 Myelopathy
Sumera, J., Sarkar, T. T., McDonald, J., Sattarnezhad, N., Nie, E., Kipp, L., … Lock, C. (2023). Epidemiological and Clinical Outcome Determinants of Post-COVID-19 Myelopathy. MULTIPLE SCLEROSIS JOURNAL. SAGE PUBLICATIONS LTD. -
A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages.
Rogawski, D., Wheeler, J., Nie, E., Zhu, W., Villanueva, E., Coffey, G., … Nagpal, S. (2024). A rare non-gadolinium enhancing sarcoma brain metastasis with microenvironment dominated by tumor-associated macrophages. Acta Neuropathologica Communications, 12(1), 15. -
Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma.
Nie, E. H., Su, Y.-J. J., Baird, J. H., Agarwal, N., Bharadwaj, S., Weng, W.-K. K., … Frank, M. J. (2024). Clinical Features of Neurotoxicity Following CD19 CAR T-cell Therapy in Mantle Cell Lymphoma. Blood Advances. -
Molecular, cellular and functional events in axonal sprouting after stroke.
Carmichael, S. T., Kathirvelu, B., Schweppe, C. A., & Nie, E. H. (2017). Molecular, cellular and functional events in axonal sprouting after stroke. Experimental Neurology, 287(Pt 3), 384–394. -
aß?-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction.
Greten-Harrison, B., Polydoro, M., Morimoto-Tomita, M., Diao, L., Williams, A. M., Nie, E. H., … Chandra, S. S. (2010). aß?-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proceedings of the National Academy of Sciences of the United States of America, 107(45), 19573–8.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
SHC- Neuro (SNHC) Palo Alto, CA
Palo Alto, CAImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records